Interestingly, we have recently shown that MSI1 contributes to a resistance against the synergistic effect of valproic acid on temozolomide in a novel combinatorial therapeutic approach for pediatric glioma (NCT03243461) [15]. Here, MSI1 is linked to central nervous system cancer.